Boston Scientific Corporation (BSX) is currently trading at $43.92. Based on 29 Wall Street analysts, the average target price is $61.00, implying a 38.9% upside. The consensus recommendation is BUY.

Over the past 30 days, the feed records 0 target raises and 4 target cuts for BSX. Over the past 90 days, the feed records 0 target raises and 19 target cuts for BSX.

BSX

Boston Scientific Corporation

HealthcareOpinion: buy

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$43.92

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$48.00$85.00
Current $43.92
Median: $60.50Mean: $62.05Current: $43.92

Recent price target updates (latest 80)

  • Wells FargoSep 24, 2026

    PT action: Lowers

    $50.00 → $48.00

  • OppenheimerSep 21, 2026

    PT action: Lowers

    $85.00 → $65.00

  • CitigroupSep 17, 2026

    PT action: Lowers

    $57.00 → $50.00

  • BTIGSep 9, 2026

    PT action: Lowers

    $60.00 → $56.00

  • TD CowenAug 25, 2026

    PT action: Maintains

    $56.00 → $56.00

  • Argus ResearchJul 31, 2026

    PT action: —

    $0.00 → $0.00

  • UBSJul 30, 2026

    PT action: Lowers

    $74.00 → $67.00

  • CitigroupJul 30, 2026

    PT action: Lowers

    $70.00 → $61.00

  • RBC CapitalJul 30, 2026

    PT action: Lowers

    $85.00 → $70.00

  • TD CowenJul 30, 2026

    PT action: Lowers

    $61.00 → $56.00

  • Canaccord GenuityJul 30, 2026

    PT action: Lowers

    $70.00 → $66.00

  • Truist SecuritiesJul 30, 2026

    PT action: Lowers

    $62.00 → $57.00

  • Evercore ISI GroupJul 30, 2026

    PT action: Lowers

    $65.00 → $55.00

  • Wells FargoJul 30, 2026

    PT action: Lowers

    $55.00 → $50.00

  • BTIGJul 29, 2026

    PT action: Lowers

    $65.00 → $60.00

  • OppenheimerJul 27, 2026

    PT action: Lowers

    $90.00 → $85.00

  • Truist SecuritiesJul 16, 2026

    PT action: Lowers

    $64.00 → $62.00

  • MizuhoJul 15, 2026

    PT action: Lowers

    $90.00 → $70.00

  • RBC CapitalJul 13, 2026

    PT action: Lowers

    $100.00 → $85.00

  • NeedhamJul 8, 2026

    PT action: Lowers

    $77.00 → $57.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$61.00

Based on 29 analysts

Analyst Recommendations

Buy (25)Hold (6)Sell (0)

Upside

+38.89%

Market Cap

$63.65B

Financial & Investment Metrics

Next Earnings Date
Oct 28, 2026D-32
P/E Ratio (TTM)17.78
Forward P/E12.87
P/B Ratio2.55
Dividend YieldN/A
Return on Equity (ROE)15.34%
Operating Margin22.90%
Debt to Equity50.15
Beta (Volatility)0.57
52 Week Range$42.20 - $105.65
LowCurrent: $43.92High

Daily editorial mentioning BSX

Price target moves

Financials and Tech Dominate Price Target Revisions as of July 16

The mid-week session saw a flurry of analyst activity across the S&P 500, with financial services and information technology firms capturing the bulk of the attention. As of the data recorded on July 16, 2026, the desks were particularly busy recalibrating expectations for heavyweights like Microsoft and a suite of banking institutions. While some firms leaned into the bullish outlooks for the tech sector, others took a more cautious stance, leading to a divergent set of target adjustments that highlight a split perspective on market momentum.

Who moved targets

The financial sector saw a string of positive revisions, suggesting analysts are finding more value in big banks as the year progresses. BMO Capital was front and center, pushing up targets for Goldman Sachs (from 1070 to 1190) and Visa (from 375 to 387). Baird followed suit, issuing upward adjustments for Wells Fargo, JPMorgan, and Bank of America, signaling a consistent sentiment across the banking landscape.

Tech names also saw significant volatility in target pricing. Mizuho, for example, made a bold statement on Fortinet by raising its target from 86 to 125, while simultaneously trimming its outlook for Microsoft. It is a common occurrence to see firms diverge on the same asset; for instance, while Evercore ISI Group raised its target on Microsoft to 525, both Mizuho and Citigroup pulled back their respective targets for the software titan to 490 and 570. Elsewhere, Tigress Financial delivered a massive jump for Palo Alto Networks, moving from 245 to 430.

Ticker Firm Direction Prior → Current
FTNT Mizuho Up 86 → 125
PANW Tigress Financial Up 245 → 430
BSX Mizuho Down 90 → 70
HCA RBC Capital Down 534 → 435

Reading the revisions

The downward movement was not limited to tech. Healthcare and energy saw notable pruning, with Mizuho adjusting Boston Scientific (from 90 to 70) and RBC Capital lowering HCA Healthcare by nearly 100 points, landing at 435. These adjustments are essential to track because they often reflect a tightening of earnings expectations in current market moves.

Energy names like Devon Energy, APA Corporation, and PR also faced downward pressure from UBS and Citigroup. Even consumer-facing stalwarts were not immune, as Citigroup opted to lower its target on McDonald’s from 375 to 335. This wave of downgrades serves as a reality check for investors, reminding us that consensus targets are moving targets, frequently reacting to sector-specific margin pressures or macroeconomic shifts. Observing these shifts in real-time provides a clearer picture of how institutional analysts are weighing the balance between growth potential and current valuation realities.

Read article →

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 8Insider Sells: 2

Whale Trades (C-Level Large Buys)

Major insider buying detected recently.

MORANO SUSAN E. (Director) - 2,040 shares

Recent Insider Transactions

DateNamePositionTransactionShares
8/25/2026MORANO SUSAN E.DirectorPurchase at price 49.22 per share.2,040
8/5/2026HABIGER DAVID CDirectorPurchase at price 47.59 per share.2,100
8/4/2026HABIGER DAVID CDirectorPurchase at price 48.07 - 48.59 per share.1,182
8/3/2026MAHONEY MICHAEL FChief Executive OfficerPurchase at price 48.33 per share.186,240
7/31/2026LUDWIG EDWARD J.DirectorPurchase at price 45.48 per share.5,000
5/20/2026LUDWIG EDWARD J.DirectorPurchase at price 56.68 per share.3,580
5/20/2026HABIGER DAVID CDirectorPurchase at price 55.92 - 56.95 per share.4,450
5/20/2026PEGUS CHERYLDirectorPurchase at price 56.49 per share.1,770
2/2/2026MAHONEY MICHAEL FChief Executive OfficerSale at price 93.49 - 94.06 per share.160,901
12/1/2025BUTCHER ARTHUR COfficerSale at price 101.55 per share.17,313

Frequently Asked Questions

Q. What is the current target price and upside for BSX?

A. The current target price for Boston Scientific Corporation is $61.00, which implies a 38.9% upside from the current price of $43.92. This is based on the consensus of 29 Wall Street analysts.

Q. What is the current analyst recommendation for BSX?

A. Currently, there are 8 Strong Buy, 17 Buy, 6 Hold, 0 Sell, and 0 Strong Sell ratings. The overall consensus is BUY.

Q. Are insiders buying BSX stock recently?

A. Over the past 6 months, there have been 8 insider buys and 2 insider sells. This can be interpreted as a positive signal.

Other Promising Stocks in Healthcare

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer →